Emeryville, CA, United States of America

Swapnil Malekar


 

 

Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2018-2021

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Swapnil Malekar

Introduction

Swapnil Malekar is a prominent inventor based in Emeryville, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for treating tendon and ligament injuries. With a total of 3 patents to his name, Malekar's work is paving the way for advancements in therapeutic applications.

Latest Patents

One of Malekar's latest patents focuses on Aza-indazole compounds for use in tendon and/or ligament injuries. The invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form. It also includes a method for manufacturing these compounds and outlines their therapeutic uses. Furthermore, the invention presents a combination of pharmacologically active agents and a pharmaceutical composition, showcasing Malekar's innovative approach to addressing medical challenges.

Career Highlights

Malekar is currently employed at Novartis AG, a leading global healthcare company. His role at Novartis allows him to collaborate with other talented professionals in the field, contributing to groundbreaking research and development. His expertise and dedication to innovation have made him a valuable asset to the company.

Collaborations

Some of Malekar's notable coworkers include Badry Bursulaya and Andreas Fisch. Their collaborative efforts enhance the research environment at Novartis, fostering creativity and innovation in the development of new therapeutic solutions.

Conclusion

In summary, Swapnil Malekar is an influential inventor whose work in pharmaceuticals is making a significant impact on the treatment of tendon and ligament injuries. His innovative patents and contributions to Novartis AG highlight his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…